Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Emergent BioSolutions Inc. (EBS)

Emergent BioSolutions CFO Lindahl to retire December 31; Frank Vargo named interim CFO

Neutral Impact 4 of 5 leadership Written later

Emergent BioSolutions said Chief Financial Officer Richard Lindahl will step down as principal financial and accounting officer effective December 31, 2026, and retire on March 31, 2027, after serving as an advisor. Frank Vargo, the company's Vice President and Treasurer, will become Interim Chief Financial Officer on January 1, 2027. The filing reports no financial results, so the change is a leadership transition rather than a change in reported performance.

Key points

  • Richard Lindahl steps down as principal financial and accounting officer effective December 31, 2026, and serves as an advisor until retiring on March 31, 2027.
  • Frank Vargo, Vice President and Treasurer, becomes Interim Chief Financial Officer on January 1, 2027.
  • Vargo's interim pay is an additional $3,850 per pay period on top of his base salary of $328,000.
  • Lindahl will help prepare the Form 10-K for the year ending December 31, 2026.

The filing

CompanyEmergent BioSolutions Inc. (EBS)
Form8-K, current report
Filed with the SECOct 16, 2026, 7:48 AM ET
Accession number0001367644-26-000098

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.